The effect of obstructive sleep apnea severity on PTSD symptoms during the course of esketamine treatment: a retrospective clinical study.
Autor: | Titone MK; VA San Diego Healthcare System, San Diego, California.; Department of Psychiatry, University of California, San Diego, San Diego, California., Hunt C; VA San Diego Healthcare System, San Diego, California., Bismark A; VA San Diego Healthcare System, San Diego, California., Nokes B; VA San Diego Healthcare System, San Diego, California., Lee E; VA San Diego Healthcare System, San Diego, California.; Department of Psychiatry, University of California, San Diego, San Diego, California., Ramanathan D; VA San Diego Healthcare System, San Diego, California.; Department of Psychiatry, University of California, San Diego, San Diego, California., Park J; VA San Diego Healthcare System, San Diego, California., Colvonen P; VA San Diego Healthcare System, San Diego, California.; Department of Psychiatry, University of California, San Diego, San Diego, California. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine [J Clin Sleep Med] 2023 Dec 01; Vol. 19 (12), pp. 2043-2051. |
DOI: | 10.5664/jcsm.10746 |
Abstrakt: | Study Objectives: Intranasal administration of esketamine is Food and Drug Administration-approved for treatment-resistant depression. In a recent retrospective case series, we show that it has promise in reducing symptoms of posttraumatic stress disorder (PTSD) as well. Untreated obstructive sleep apnea (OSA) is prevalent among veterans with PTSD and has been shown to interfere with other PTSD treatments. In the current study, we examined whether OSA impacts esketamine's effectiveness in reducing symptoms of PTSD or depression. Methods: Participants were 60 veterans with a diagnosis of major depressive disorder and PTSD who received intranasal esketamine treatment at the San Diego Veterans Affairs (VA) Medical Center. We used growth-curve modeling to examine changes in depression and PTSD symptoms following esketamine treatments and, in the subset of individuals screened for OSA (n = 24, all prescribed positive airway pressure therapy), examined the impacts of OSA severity on these trajectories. Results: We first showed that both PTSD and depressive symptoms significantly decreased over the course of esketamine treatment. In the subset of veterans screened for OSA, individuals with lower OSA severity reported the greatest reduction in PTSD symptoms, while veterans with the most severe OSA reported the least reduction in PTSD symptoms. Depression response was not affected by severity of OSA in this analysis. Conclusions: Veterans with PTSD and depression tend to benefit from esketamine treatment, but OSA may interfere with esketamine effectiveness. Comorbid OSA should be assessed for and treated to maximize esketamine's benefits in PTSD. Citation: Titone MK, Hunt C, Bismark A, et al. The effect of obstructive sleep apnea severity on PTSD symptoms during the course of esketamine treatment: a retrospective clinical study. J Clin Sleep Med . 2023;19(12):2043-2051. (© 2023 American Academy of Sleep Medicine.) |
Databáze: | MEDLINE |
Externí odkaz: |